Prosigna Breast Cancer Prognostic Gene Signature Assay study published in JCO

[News]

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that the TransATAC clinical validation study for its Prosigna Breast Cancer Prognostic Gene Signature Assay, which is based on the PAM50 gene signature, was published in the Journal of Clinical Oncology.

More... (http://www.news-medical.net/news/20130702/Prosigna-Breast-Cancer-Prognostic-Gene-Signature-Assay-study-published-in-JCO.aspx)